CLINICAL_TRIALS
trial_result
· 2014-04-30
Clinical Trial Update: Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) [Phase 3]
Summary
A Phase 3 clinical trial evaluating NX-1207 for benign prostatic hyperplasia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nymox Corporation | Conditions: Benign Prostatic Hyperplasia | Phase 3 | Status: COMPLETED